Research ArticleNuclear Oncology
Pharmacokinetics, Dosimetry and Toxicity of Rhenium-188-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody, MN-14, in Gastrointestinal Cancer
Malik Juweid, Robert M. Sharkey, Lawrence C. Swayne, Gary L. Griffiths, Robert Dunn and David M. Goldenberg
Journal of Nuclear Medicine January 1998, 39 (1) 34-42;
Malik Juweid
Robert M. Sharkey
Lawrence C. Swayne
Gary L. Griffiths
Robert Dunn
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetics, Dosimetry and Toxicity of Rhenium-188-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody, MN-14, in Gastrointestinal Cancer
Malik Juweid, Robert M. Sharkey, Lawrence C. Swayne, Gary L. Griffiths, Robert Dunn, David M. Goldenberg
Journal of Nuclear Medicine Jan 1998, 39 (1) 34-42;
Pharmacokinetics, Dosimetry and Toxicity of Rhenium-188-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody, MN-14, in Gastrointestinal Cancer
Malik Juweid, Robert M. Sharkey, Lawrence C. Swayne, Gary L. Griffiths, Robert Dunn, David M. Goldenberg
Journal of Nuclear Medicine Jan 1998, 39 (1) 34-42;
Jump to section
Related Articles
- No related articles found.
Cited By...
- SPECT- and Fluorescence Image-Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen-Targeting Antibody
- Current Status of Therapy of Solid Tumors
- Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT